Zimmer Biomet (ZBH) Earns Daily Media Sentiment Score of 0.15
Headlines about Zimmer Biomet (NYSE:ZBH) have been trending somewhat positive on Sunday, Accern Sentiment reports. Accern identifies positive and negative media coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Zimmer Biomet earned a coverage optimism score of 0.15 on Accern’s scale. Accern also assigned news articles about the medical equipment provider an impact score of 46.1695555811803 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
Here are some of the media stories that may have effected Accern’s rankings:
- Stonerise Capital Management LLC Has $10.86 Million Position in Zimmer Biomet Holdings Inc (ZBH) (americanbankingnews.com)
- Zimmer Biomet Holdings Inc (ZBH) Stake Lifted by First Trust Advisors LP (americanbankingnews.com)
- Zimmer Biomet Holdings, Inc. (ZBH) : Are you searching Analysts Rated Stock – Wall Street Morning (wallstreetmorning.com)
- Amalgamated Bank Acquires 2,265 Shares of Zimmer Biomet Holdings Inc (ZBH) (americanbankingnews.com)
- Zimmer Biomet Holdings Inc (ZBH) Holdings Trimmed by Raymond James Financial Services Advisors Inc. (americanbankingnews.com)
ZBH has been the subject of a number of research reports. Royal Bank of Canada cut their target price on shares of Zimmer Biomet to $125.00 and set an “outperform” rating for the company in a research report on Tuesday, November 7th. Morgan Stanley cut their target price on shares of Zimmer Biomet from $150.00 to $148.00 and set an “overweight” rating for the company in a research report on Monday, February 26th. Citigroup cut their target price on shares of Zimmer Biomet from $132.00 to $121.00 and set a “neutral” rating for the company in a research report on Tuesday, February 27th. Needham & Company LLC lifted their target price on shares of Zimmer Biomet from $144.00 to $155.00 and gave the stock a “strong-buy” rating in a research report on Tuesday, January 30th. Finally, BMO Capital Markets restated a “buy” rating and set a $142.00 target price on shares of Zimmer Biomet in a research report on Tuesday, December 12th. Two investment analysts have rated the stock with a sell rating, four have issued a hold rating, seventeen have given a buy rating and one has given a strong buy rating to the company’s stock. The company currently has an average rating of “Buy” and an average price target of $141.06.
Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings data on Tuesday, January 30th. The medical equipment provider reported $2.10 earnings per share for the quarter, meeting analysts’ consensus estimates of $2.10. Zimmer Biomet had a net margin of 23.51% and a return on equity of 15.45%. The business had revenue of $2.07 billion during the quarter, compared to analyst estimates of $2.03 billion. During the same quarter in the previous year, the business posted $2.14 earnings per share. The company’s revenue was up 3.0% on a year-over-year basis. equities analysts expect that Zimmer Biomet will post 7.82 earnings per share for the current year.
In related news, insider Bryan C. Hanson bought 25,077 shares of the stock in a transaction that occurred on Tuesday, February 20th. The stock was purchased at an average cost of $119.68 per share, for a total transaction of $3,001,215.36. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, VP Chad F. Phipps sold 20,826 shares of the business’s stock in a transaction that occurred on Monday, February 12th. The shares were sold at an average price of $115.95, for a total transaction of $2,414,774.70. The disclosure for this sale can be found here. 1.07% of the stock is currently owned by insiders.
COPYRIGHT VIOLATION NOTICE: This piece of content was first published by Daily Political and is the property of of Daily Political. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this piece of content can be viewed at https://www.dailypolitical.com/2018/03/04/zimmer-biomet-zbh-earns-daily-media-sentiment-score-of-0-15.html.
About Zimmer Biomet
Zimmer Biomet Holdings, Inc is engaged in designing, manufacturing and marketing of orthopedic reconstructive products; sports medicine, biologics, extremities and trauma products; office-based technologies; spine, craniomaxillofacial and thoracic products; dental implants, and related surgical products.
Receive News & Ratings for Zimmer Biomet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zimmer Biomet and related companies with MarketBeat.com's FREE daily email newsletter.